PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32192322-0 2021 Efficacy of hypofractionated radiotherapy combined with docetaxel in middle and advanced non-small cell lung cancer and its effects on serum MMP-9 and VEGF expressions. Docetaxel 56-65 matrix metallopeptidase 9 Homo sapiens 141-146 30217885-0 2018 Retraction: Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-kappaB (RANK)/RANK Ligand/MMP-9 Signaling in Prostate Cancer. Docetaxel 55-64 matrix metallopeptidase 9 Homo sapiens 192-197 25514117-11 2015 Summarizing, present study clearly showed that DTX inhibited Wnt/beta-catenin signalling pathways and significantly reduced the matrix metallopeptodase 9 (MMP-9) protein expressions and its activity. Docetaxel 47-50 matrix metallopeptidase 9 Homo sapiens 128-153 29288085-3 2018 In addition, confocal microscopy, flow cytometry and in vitro transfection analyses demonstrated more efficient cellular internalization of DTX and MMP-9 shRNA after incubation with PAG/DTX- MMP-9 shRNA micelles (PAG/DTX-shRNA) than with free drugs. Docetaxel 140-143 matrix metallopeptidase 9 Homo sapiens 191-196 29288085-3 2018 In addition, confocal microscopy, flow cytometry and in vitro transfection analyses demonstrated more efficient cellular internalization of DTX and MMP-9 shRNA after incubation with PAG/DTX- MMP-9 shRNA micelles (PAG/DTX-shRNA) than with free drugs. Docetaxel 186-189 matrix metallopeptidase 9 Homo sapiens 148-153 29288085-3 2018 In addition, confocal microscopy, flow cytometry and in vitro transfection analyses demonstrated more efficient cellular internalization of DTX and MMP-9 shRNA after incubation with PAG/DTX- MMP-9 shRNA micelles (PAG/DTX-shRNA) than with free drugs. Docetaxel 186-189 matrix metallopeptidase 9 Homo sapiens 191-196 29288085-3 2018 In addition, confocal microscopy, flow cytometry and in vitro transfection analyses demonstrated more efficient cellular internalization of DTX and MMP-9 shRNA after incubation with PAG/DTX- MMP-9 shRNA micelles (PAG/DTX-shRNA) than with free drugs. Docetaxel 186-189 matrix metallopeptidase 9 Homo sapiens 148-153 29288085-3 2018 In addition, confocal microscopy, flow cytometry and in vitro transfection analyses demonstrated more efficient cellular internalization of DTX and MMP-9 shRNA after incubation with PAG/DTX- MMP-9 shRNA micelles (PAG/DTX-shRNA) than with free drugs. Docetaxel 186-189 matrix metallopeptidase 9 Homo sapiens 191-196 25514117-11 2015 Summarizing, present study clearly showed that DTX inhibited Wnt/beta-catenin signalling pathways and significantly reduced the matrix metallopeptodase 9 (MMP-9) protein expressions and its activity. Docetaxel 47-50 matrix metallopeptidase 9 Homo sapiens 155-160 16651437-0 2006 Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Docetaxel 43-52 matrix metallopeptidase 9 Homo sapiens 180-185 24489574-2 2013 We previously reported the profiles of tumor infiltrating leukocytes in cutaneous angiosarcoma (AS) and suggested that a combination of docetaxel (DTX) with bisphosphonate risedronate sodium (RS) might be effective for MMP9-expressing AS by targeting immunosuppressive cells such as M2 macrophages. Docetaxel 136-145 matrix metallopeptidase 9 Homo sapiens 219-223 24489574-2 2013 We previously reported the profiles of tumor infiltrating leukocytes in cutaneous angiosarcoma (AS) and suggested that a combination of docetaxel (DTX) with bisphosphonate risedronate sodium (RS) might be effective for MMP9-expressing AS by targeting immunosuppressive cells such as M2 macrophages. Docetaxel 147-150 matrix metallopeptidase 9 Homo sapiens 219-223 24576804-4 2014 For co-delivery analysis, the obtained PP-PLLD-Arg/DOC/MMP-9 complexes could induce a more significant apoptosis than DOC or MMP-9 used only, and decreased invasive capacity of HNE-1 cells. Docetaxel 51-54 matrix metallopeptidase 9 Homo sapiens 55-60 24576804-4 2014 For co-delivery analysis, the obtained PP-PLLD-Arg/DOC/MMP-9 complexes could induce a more significant apoptosis than DOC or MMP-9 used only, and decreased invasive capacity of HNE-1 cells. Docetaxel 51-54 matrix metallopeptidase 9 Homo sapiens 125-130 24576804-4 2014 For co-delivery analysis, the obtained PP-PLLD-Arg/DOC/MMP-9 complexes could induce a more significant apoptosis than DOC or MMP-9 used only, and decreased invasive capacity of HNE-1 cells. Docetaxel 118-121 matrix metallopeptidase 9 Homo sapiens 55-60 23867803-4 2013 These findings suggest that a high number of immunosuppressive cells might be related to the prognosis of AS, and that a combination of docetaxel with bisphosphonate risedronate sodium might be effective for MMP-9-expressing AS. Docetaxel 136-145 matrix metallopeptidase 9 Homo sapiens 208-213 22308113-0 2012 Successful Treatment of MMP-9-Expressing Angiosarcoma with Low-Dose Docetaxel and Bisphosphonate. Docetaxel 68-77 matrix metallopeptidase 9 Homo sapiens 24-29 21323568-4 2011 In a Bayesian log-normal regression model for PFS, a rise in human matrix metalloproteinase 9 after docetaxel alone associated with a longer PFS. Docetaxel 100-109 matrix metallopeptidase 9 Homo sapiens 67-93 21323568-7 2011 The predictive value of human matrix metalloproteinase 9 kinetics for docetaxel efficacy requires prospective validation. Docetaxel 70-79 matrix metallopeptidase 9 Homo sapiens 30-56 16651437-10 2006 Moreover, genistein down-regulated the expression and activity of MMP-9, which was induced by docetaxel treatment, and inhibited invasion of PC-3 cells. Docetaxel 94-103 matrix metallopeptidase 9 Homo sapiens 66-71 16651437-11 2006 These results suggest that the observed potentiation of antitumor activity of docetaxel by genistein in the SCID-human model of experimental bone metastasis could be mediated by regulation of OPG/RANK/RANKL/MMP-9 signaling, resulting in the inhibition of osteoclastic bone resorption and prostate cancer bone metastasis. Docetaxel 78-87 matrix metallopeptidase 9 Homo sapiens 207-212 12970892-4 2003 Compared with the solvent control group, 0.1, 0.5, 1.0 ng/ml of docetaxel could downregulate the expression of VEGF, bFGF, MMP 2 and MMP 9 and suppress the activity of gelatinase. Docetaxel 64-73 matrix metallopeptidase 9 Homo sapiens 133-138